acute%20pericarditis
ACUTE PERICARDITIS

Pericarditis is the inflammation of the pericardial sac and accounts for 5% of visits to the emergency room for chest pain without myocardial infarction.

The patient experiences chest pain that is sharp, pleuritic and improves with sitting up and leaning forward.

Acute pericarditis is characterized by new-onset pericarditis with at least 2 of the following:

  • Pericarditic chest pain
  • Pericardial friction rubs
  • New or worsening pericardial effusion
  • ECG finding of a new diffuse ST-segment elevation or PR depression
Drug Information

Indication: Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; rel...

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Adjuvant of a maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylit...

Indication: Severe hypersensitivity & dermatological reaction; severe acute & chronic inflammatory & allergic ...

Indication: Adjunctive therapy for short-term management of acute episode or exacerbation post-traumatic OA, synovitis or ...

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 3 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.